AbbVie's dividend is a very appealing factor.
Johnson & Johnson has a rare and impressive streak of consecutive annual dividend increases. Merck is facing multiple ...
Johnson & Johnson is diving head-first into the deep end of the competitive robotic surgery market. The payoff for investors won't happen overnight, but management believes it will be worth the wait.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results